Lifespan Vision Ventures is pleased to announce that its portfolio company, Remedium Bio, Inc. ("Remedium"), has entered into a multi-target research and development collaboration with Eli Lilly and Company ("Lilly") focused on advancing innovative gene therapies for Type 2 diabetes and obesity.

This partnership underscores the promise of Remedium's proprietary Prometheus™ platform and the company's leadership in developing long-acting, adjustable-dose therapeutics for major unmet medical needs. This approach aims to replace repeated protein-based injections with a safer, more consistent, and more cost-effective treatment, enabling genetic medicine to address common conditions across endocrinology, immunology, and cardiometabolic disease safely, effectively, and at scale.

"We congratulate Frank and the Remedium team on this important milestone with Lilly," said Andrew Worden, Founding Partner at Lifespan Vision Ventures. "It is a powerful validation of their platform and is an important step toward developing interventions that extend healthspan. We're excited to support Remedium as they scale their platform and translate it into therapies that can benefit millions of patients."